Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: The Northern Manhattan Study

Metabolism: Clinical and Experimental

Volumn 63, Issue 9, 2014, Pages 1125-1130

  Hudson, Barry I ^a   Dong, Chuanhui ^a   Gardener, Hannah ^a   Elkind, Mitchell S V ^b,c   Wright, Clinton B ^a   Goldberg, Ron ^a   Sacco, Ralph L ^a   Rundek, Tatjana ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Neurology Leonard M Miller School of Medicine University of Miami ^*  (United States)

^c Department of Epidemiology and Public Health Leonard M Miller School of Medicine University of Miami ^*  (United States)

Author keywords

Biomarker; Cardiovascular disease; Diabetes; Metabolic syndrome; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; DIET RESTRICTION; ELEVATED BLOOD PRESSURE; ETHNIC GROUP; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; WAIST CIRCUMFERENCE;

BIOMARKER; CARDIOVASCULAR DISEASE; DIABETES; METABOLIC SYNDROME; RAGE;

AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; NEW YORK CITY; OBESITY, ABDOMINAL; PREVALENCE; RECEPTORS, IMMUNOLOGIC; SOLUBILITY; URBAN HEALTH; WAIST CIRCUMFERENCE;

EID: 84906264692     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.05.011     Document Type: Article

References (22)

1. S.M. Grundy Metabolic syndrome pandemic Arterioscler Thromb Vasc Biol 28 2008 629 636
2. B. Boden-Albala, R.L. Sacco, H.S. Lee, C. Grahame-Clarke, T. Rundek, and M.V. Elkind et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study Stroke 39 2008 30 35
3. A.Z. Kalea, A.M. Schmidt, and B.I. Hudson RAGE: a novel biological and genetic marker for vascular disease Clin Sci (Lond) 116 2009 621 637
4. H. Ueno, H. Koyama, T. Shoji, M. Monden, S. Fukumoto, and S. Tanaka et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse Atherosclerosis 211 2010 431 436
5. M. Monden, H. Koyama, Y. Otsuka, T. Morioka, K. Mori, and T. Shoji et al. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2 Diabetes 62 2013 478 489
6. K. Sebekova, Z. Krivosikova, and M. Gajdos Total plasma Nepsilon-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects Clin Chem Lab Med 2013 1 11
7. H. Momma, K. Niu, Y. Kobayashi, C. Huang, M. Chujo, and A. Otomo et al. Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study J Clin Endocrinol Metab 99 2014 587 593
8. G.D. Norata, K. Garlaschelli, L. Grigore, G. Tibolla, S. Raselli, and L. Redaelli et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population Nutr Metab Cardiovasc Dis 19 2009 129 134
9. R.L. Sacco, B. Boden-Albala, G. Abel, I.F. Lin, M. Elkind, and W.A. Hauser et al. Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study Stroke 32 2001 1725 1731
10. B.I. Hudson, Y.P. Moon, A.Z. Kalea, M. Khatri, C. Marquez, and A.M. Schmidt et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS) Atherosclerosis 216 2011 192 198
11. J.B. Lindsey, J.A. de Lemos, F. Cipollone, C.R. Ayers, A. Rohatgi, and D.A. Morrow et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study Diabetes Care 32 2009 1218 1220
12. H.M. Colhoun, D.J. Betteridge, P. Durrington, G. Hitman, A. Neil, and S. Livingstone et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial Diabetes 60 2011 2379 2385
13. E. Selvin, M.K. Halushka, A.M. Rawlings, R.C. Hoogeveen, C.M. Ballantyne, and J. Coresh et al. sRAGE and risk of diabetes, cardiovascular disease, and death Diabetes 62 2013 2116 2121
14. J.W. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, and H.H. Parving et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study Diabetes 59 2010 2027 2032
15. M.C. Thomas, J. Soderlund, M. Lehto, V.P. Makinen, J.L. Moran, and M.E. Cooper et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes Diabetologia 54 2011 2669 2677
16. C. Falcone, E. Emanuele, A. D'Angelo, M.P. Buzzi, C. Belvito, and M. Cuccia et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler Thromb Vasc Biol 25 2005 1032 1037
17. H. Koyama, S. Tanaka, M. Monden, T. Shoji, T. Morioka, and S. Fukumoto et al. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE) Atherosclerosis 234 2014 329 334
18. N. Marx, D. Walcher, N. Ivanova, K. Rautzenberg, A. Jung, and R. Friedl et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products Diabetes 53 2004 2662 2668
19. H.L. Tam, S.W. Shiu, Y. Wong, W.S. Chow, D.J. Betteridge, and K.C. Tan Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes Atherosclerosis 209 2010 173 177
20. J.M. Forbes, S.R. Thorpe, V. Thallas-Bonke, J. Pete, M.C. Thomas, and E.R. Deemer et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy J Am Soc Nephrol 16 2005 2363 2372
21. Y. Jang, J.Y. Kim, S.M. Kang, J.S. Kim, J.S. Chae, and O.Y. Kim et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans Metabolism 56 2007 199 205
22. L. Yang, Q. Wu, Y. Li, X. Fan, Y. Hao, and H. Sun et al. Association of the receptor for advanced glycation end products gene polymorphisms and circulating RAGE levels with diabetic retinopathy in the Chinese population J Diabetes Res 2013 2013 [264579]